SCHEMBL6299303

SCHEMBL6299303

O=Cc1ccc(CO)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
ALDH1A3 P47895 3/20 0.45
ALDH3A1 P30838 2/20 0.45
KDM4E B2RXH2 1/20 0.42
PTGS2 P35354 1/20 0.42
RAB9A P51151 1/20 0.42
VCAM1 P19320 1/20 0.42
HSD17B10 Q99714 2/20 0.41
TTR P02766 1/20 0.39
NR3C1 P04150 1/20 0.38
PGR P06401 1/20 0.38
NR3C2 P08235 1/20 0.38
CYP1A2 P05177 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
ALDH5A1 P51649 2/20 0.37
ABAT P80404 2/20 0.37
PTGER4 P35408 1/20 0.36
AOX1 Q06278 1/20 0.35
TRIM24 O15164 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405003 0.85 ALDH1A1 (0.53) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL25371194 0.84 ALDH1A1 (0.57) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL6015146 0.82 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL2601956 0.81 KDM4E (0.46) ALDH1A1KDM4EPTGS2RAB9AHSD17B10
SCHEMBL14321571 0.80 ALDH1A1 (0.57) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL3657410 0.80 ALDH1A1 (0.57) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL6299014 0.80 ALDH1A1 (0.39) ALDH1A1CYP1A2TDP1TSHR
SCHEMBL25368450 0.78 ALDH1A1 (0.46) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2
SCHEMBL5521189 0.78 KDM4E (0.59) ALDH1A1KDM4EPTGS2RAB9AHSD17B10
SCHEMBL27958719 0.77 ALDH1A1 (0.53) ALDH1A1ALDH1A3ALDH3A1KDM4EPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
CN-1268942-A Sulfonamide compounds and medicinal use thereof FUJISAWA PHARMACEUTICAL CO (JP) 2000-10-04 CN disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 ALDH1A1 570/4885ALDH1A3 468/4885ALDH3A1 342/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM ALDH1A1 1067/4885ALDH1A3 476/4885ALDH3A1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.